Technical / White Paper

Biomarkers of Toxicity Panel in Clinical Trials

Format: PDF file | Document type: Technical / White Paper | Promoted Content

This content is provided by ACM Global Central Laboratory, and any views and opinions expressed do not necessarily reflect those of

Biomarkers of Toxicity Panel in Clinical Trials

Most drug candidates are discontinued because of induced organ toxicity and half of them owe this to liver toxicity. This issue explains why drug developers need to be aware of the latest options for liver and kidney laboratory safety testing, and understand the importance of testing a combination of novel, early predictive toxicity biomarkers, along with the conventional tests.

Related resources from ACM Global Central Laboratory

Supplier info centre